Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis

Bone Marrow Transplant. 1998 Oct;22(8):755-61. doi: 10.1038/sj.bmt.1701423.

Abstract

Among 551 consecutive recipients of allogeneic bone marrow transplants, 451 survived more than 3 months and were evaluated for chronic graft-versus-host disease (GVHD). Most of the donors were HLA-identical siblings or parents (n = 334). Patients with HLA-mismatched donors (n = 30) and matched unrelated donors (MUD) (n = 87) were also included in the study. In the analysis of all patients, the 5-year cumulative incidence of chronic GVHD was 45%. We analysed 34 risk factors. High recipient age was the single most important risk factor (P < 0.001). Other significant risk factors in multivariate analysis were: acute GVHD grades I-IV (P < 0.001), immune female donor to male recipient (P = 0.006) and chronic myelogenous leukaemia (CML), compared with all other diagnoses (P = 0.014). The cumulative 5-year incidence of chronic GVHD, with no significant risk factors present, was 9%, 29% with one risk factor, 53% with two, 68% with three and 75% with all four risk factors present. In patients with HLA-identical sibling donors and GVHD prophylaxis consisting of a combination of methotrexate (MTX) and cyclosporin A (CsA) (n = 208), increasing recipient age (P < 0.001) and CML (P = 0.007), were found to be significant risk factors for chronic GVHD. Finally, a multivariate analysis in recipients of bone marrow from unrelated donors (n = 89) showed recipient age alone (P = 0.006) to be significantly associated with chronic GVHD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Bone Marrow Transplantation / immunology*
  • Child
  • Child, Preschool
  • Chronic Disease
  • Cyclosporine / therapeutic use
  • Female
  • Graft vs Host Disease / etiology*
  • Graft vs Host Disease / prevention & control
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Infant
  • Male
  • Methotrexate / therapeutic use
  • Middle Aged
  • Neoplasms / therapy*
  • Retrospective Studies
  • Risk Factors
  • Sex Factors
  • Transplantation, Homologous

Substances

  • Immunosuppressive Agents
  • Cyclosporine
  • Methotrexate